

WHAT IS CLAIMED IS:

*sub  
as*

1. LK6 protein (SEQ ID NO: 4) consisting of amino acid sequences of human apolipoprotein(a) kringle domains IV36.
2. LK7 protein (SEQ ID NO: 6) consisting of amino acid sequences of human apolipoprotein(a) kringle domains IV37.
3. LK8 protein (SEQ ID NO: 8) consisting of amino acid sequences of human apolipoprotein(a) kringle domains V38.
4. LK68 protein (SEQ ID NO: 2) consisting of amino acid sequences of human apolipoprotein(a) kringle domains IV36, IV37 and V38 in a serial manner
5. A cDNA sequence (SEQ ID NO: 3) which codes for the LK6 protein of claim 1.
6. A cDNA sequence (SEQ ID NO: 5) which codes for the LK7 protein of claim 2.
7. A cDNA sequence (SEQ ID NO: 7) which codes for the LK8 protein of claim 3.
8. A cDNA sequence (SEQ ID NO: 1) which codes for the LK68 protein of claim 4.
9. A recombinant expression vector pET15b/LK6 comprising the cDNA of claim 5 which expresses the LK6 protein of claim 1.
10. A recombinant expression vector pET15b/LK7 comprising the cDNA of claim 6 which expresses the LK7 protein of claim 2.

11. A recombinant expression vector pET15b/LK8 comprising the cDNA of claim 7 which expresses the LK8 protein of claim 3.

5

12. A recombinant expression vector pET11a/LK68 comprising the cDNA of claim 8 which expresses the LK68 protein of claim 4.

10

13. *Escherichia coli* BL21(DE3)/LK6(KCTC0655BP) transformed with the recombinant expression vector pET15b/LK6 of claim 9.

15

14. *Escherichia coli* BL21(DE3)/LK7(KCTC0656BP) transformed with the recombinant expression vector pET15b/LK7 of claim 10.

20

15. *Escherichia coli* BL21/LK8(KCTC0634BP) transformed with the recombinant expression vector pET15b/LK8 of claim 11.

25

16. *Escherichia coli* BL21/LK6-8(KCTC0633BP) transformed with the recombinant expression vector pET11a/LK68 of claim 12.

30

17. An anticancer agent which comprises an active ingredient of LK68 protein, its single kringles, or their functional equivalents and pharmaceutically acceptable carrier.

35

18. A method for treating angiogenesis-mediated disease which comprises administering therapeutically effective amount of LK 68 protein, its single kringles, or their functional equivalents to a human or animal.

19. The method for treating angiogenesis-mediated disease of claim 18, wherein the angiogenesis-mediated

disease is cancer, rheumatoid arthritis, psoriasis, or ocular angiogenic disease.